Sergejew T, Forgiarini P, Schnebli H P
Novartis Pharma AG, Basle, Switzerland.
Br J Haematol. 2000 Sep;110(4):985-92. doi: 10.1046/j.1365-2141.2000.02260.x.
In order to test new orally active iron chelators in a predictive way, a primate model has been developed. This model makes use of the marmoset monkey (Callithrix jacchus) and its overall design is similar to a previously reported monkey model. However, this new model enables a higher compound throughput and requires lower amounts of test compound because the animals are much easier to handle and have much lower body weights. The marmosets were iron-overloaded by three intraperitoneal injections of iron (III) hydroxide polyisomaltose. For the iron-balance studies, the animals were kept in metabolic cages and were maintained on a low-iron diet in order to reduce faecal background. After compound administration, the excretion of iron in urine and faeces was followed for 2 d. A series of well-known chelators was tested for validation of the model. In particular, comparison of the iron-clearing properties of DFO, L1, CP94 and HBED in marmosets and humans demonstrated the predictive value of the model and justify our expectation that if iron chelators such as CGP65015, ICL670A and CGP75254A are active in marmosets, they will be active in humans as well.
为了以一种可预测的方式测试新型口服活性铁螯合剂,已开发出一种灵长类动物模型。该模型利用狨猴(Callithrix jacchus),其总体设计与先前报道的猴子模型相似。然而,这种新模型能够实现更高的化合物通量,并且所需的测试化合物量更低,因为这些动物更容易处理且体重更低。通过腹腔注射三次氢氧化铁聚异麦芽糖使狨猴铁过载。为了进行铁平衡研究,将动物饲养在代谢笼中,并维持低铁饮食以减少粪便背景。给予化合物后,跟踪尿液和粪便中铁的排泄情况2天。测试了一系列知名螯合剂以验证该模型。特别是,比较去铁胺(DFO)、L1、CP94和HBED在狨猴和人类中的铁清除特性,证明了该模型的预测价值,并证明了我们的预期是合理的,即如果铁螯合剂如CGP65015、ICL670A和CGP75254A在狨猴中具有活性,那么它们在人类中也将具有活性。